当前位置：
说明书下载产品属性/ Product Details
| 产品名称 | Recombinant Human TGF-beta 1 | 蛋白编号 | P01137 |
| 产品别称 | Transforming Growth Factor Beta-1; TGF-Beta-1; Latency-Associated Peptide; LAP; TGFB1; TGFB | ||
| 产品描述 | Recombinant Human Transforming Growth Factor Beta 1 is produced by our Mammalian expression system and the target gene encoding Ala279-Ser390 is expressed. | ||
| 分子量 | Mol Mass:12.8 KDa; APMol Mass:13 KDa, reducing conditions | 剂型描述 | Lyophilized from a 0.2 μm filtered solution of 50mM Glycine-HCl, 150mM NaCl, pH 2.5. |
| 内毒素 | < 0.01 EU/µg as determined by LAL test. | 纯度 | Greater than 95% as determined by reducing SDS-PAGE. (QC verified) |
| 生物活性 | Measured by its ability to inhibit the IL-4-dependent proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 4-40 pg/ml. (QC verified) | ||
| 复溶 | Always centrifuge tubes before opening.Do not mix by vortex or pipetting. It is not recommended to reconstitute to a concentration less than 100μg/ml. Dissolve the lyophilized protein in distilled water. Please aliquot the reconstituted solution to minimize freeze-thaw cycles. | ||
| 保存条件 | Lyophilized protein should be stored at ≤ -20°C, stable for one year after receipt. Reconstituted protein solution can be stored at 2-8°C for 2-7 days. Aliquots of reconstituted samples are stable at ≤ -20°C for 3 months. | ||
| 运输条件 | The product is shipped at ambient temperature. Upon receipt, store it immediately at the temperature listed below. | ||
| 产品背景 | Transforming Growth Factor β-1 (TGFβ-1) is a secreted protein which belongs to the TGF-β family. TGFβ-1 is abundantly expressed in bone, articular cartilage and chondrocytes and is increased in osteoarthritis (OA). TGFβ-1 performs many cellular functions, including the control of cell growth, cell proliferation, cell differentiation and apoptosis. The precursor is cleaved into a latency-associated peptide (LAP) and a mature TGFβ-1 peptide. TGFβ-1 may also form heterodimers with other TGFβ family members. It has been found that TGFβ-1 is frequently upregulated in tumor cells. Mutations in this gene results in Camurati-Engelmann disease. | ||
-
Greater than 95% as determined by reducing SDS-PAGE. (QC verified)
-
Measured by its ability to inhibit the IL-4-dependent proliferation of TF‑1 human erythroleukemic cells. The ED50 for this effect is 4-40 pg/ml. (QC verified)